Comparative Pharmacology
Head-to-head clinical analysis: NORLUTATE versus PROGESTERONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NORLUTATE versus PROGESTERONE.
NORLUTATE vs PROGESTERONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Progestin that suppresses gonadotropin secretion, inhibits ovulation, and induces endometrial transformation.
Progesterone binds to progesterone receptors (PR-A and PR-B) in target tissues, modulating gene expression to induce secretory changes in the endometrium, support pregnancy, and regulate gonadotropin secretion via negative feedback on the hypothalamic-pituitary axis.
5 mg orally once daily for 5 days, starting on day 1 of menstrual cycle; for menorrhagia, 5 mg orally three times daily from day 19 to day 26 of cycle.
Oral: 200-400 mg daily in 1-2 divided doses; Intramuscular: 50-100 mg daily; Vaginal: 200-400 mg daily in 1-2 divided doses.
None Documented
None Documented
Clinical Note
moderateMedroxyprogesterone acetate + Digoxin
"Medroxyprogesterone acetate may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateHydroxyprogesterone caproate + Digoxin
"Hydroxyprogesterone caproate may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateMedroxyprogesterone acetate + Digitoxin
"Medroxyprogesterone acetate may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateHydroxyprogesterone caproate + Digitoxin
Terminal elimination half-life is approximately 5-6 hours. Clinical context: supports twice-daily dosing; steady state reached within 2 days.
Elimination half-life: approximately 5-15 minutes for intravenous progesterone; terminal half-life of metabolites (pregnanediol) is about 2-8 hours, but clinical effects (e.g., endometrial transformation) persist for days due to receptor-mediated activity.
Primarily renal (approximately 60% of metabolites, mostly glucuronides), with about 40% fecal/biliary elimination. Less than 1% excreted unchanged.
Renal (50-60% as metabolites) and fecal (10-20%). Biliary excretion of metabolites occurs; enterohepatic recirculation may contribute to prolonged presence. Unchanged drug negligible in urine.
Category C
Category D/X
Progestin
Progestin
"Hydroxyprogesterone caproate may decrease the cardiotoxic activities of Digitoxin."